Real-time SEC Filing Alerts & Continuous Market Intelligence

Automated monitoring and AI summaries for SEC, FDA, EPA, and government filings — delivered to your Inbox.

8:00 AM:
Before-Market
Digest {}
Real-time Alerts
{ ALERT }:$AAPL 10-K //
10:30 AM:
Morning Momentum
Digest //
12:30 PM:
Midday Pulse
Digest {}
Real-time Alerts
{ ALERT }:$XOM Form 4 }
1:15 PM:
Mid-Market
Digest {}
Real-time Alerts
{ ALERT }:$DAL 8-K }
Real-time Alerts
{ ALERT }:$PEP DEF 14A }
3:00 PM:
Power Hour
Digest {}
6:00 PM:
Evening Edge
Digest //
Real-time Alerts
{ ALERT }:$NVDA S-1 }
9:00 PM:
Daily Digest {}
8:00 AM:
Before-Market Digest {}
Real-time
$AAPL 10-K Alert //
10:30 AM:
Morning Momentum //
12:30 PM:
Midday Pulse Digest {}
1:15 PM:
Mid-Market Digest {}
3:00 PM:
Power Hour Digest {}
6:00 PM:
Evening Edge Digest //
9:00 PM:
Daily Digest {}
Continuous Advantage

The market never sleeps. Neither does our engine.

Stop waiting for end-of-day summaries. Catch catalysts as they happen with an uninterrupted flow of distilled market intelligence.

Gunpowder
Sent:9:00 PM ET{}

Daily USA Market Intelligence

March 10, 2026
Filings Analyzed
50from Mar 10
Executive Summary
50 filings analyzedMarch 10, 2026
Across 50 SEC filings for March 10, 2026, dominant themes include widespread equity dilution from ATM offerings, private placements, and shelf registrations (e.g., Trio Petroleum $17.4M sold/18.1M shares, Aclaris $39.8M/12.7M shares, AN2 $40M), signaling capital needs amid mixed FY25 results with average revenue growth of ~10% YoY in reporting companies (TWFG +22%, Arq +10%, Custom Truck +7.9%) but frequent net loss widening (Bullish -$785M vs +$80M, Arq -$52.6M vs -$5.1M, Trailblazer -$8.3M vs +$0.28M) driven by impairments and fair value hits. Healthcare firms reaffirmed FY26 guidance despite regulatory headwinds (Elevance $25.50+ EPS amid CMS sanctions effective March 31, Centene >$3.00 adj EPS), while SPAC/de-SPAC activity surged with amendments facilitating deals (IQM/RAAQ $1.8B value, Horizon Quantum PIPE $111.9M). Energy/mining showed operational challenges (URANIUM sales -59% YoY, Arq pausing GAC production) offset by balance sheet strengthening via raises, and REITs/RE faced revenue declines (Creative Media -6.3%, ACRES NII -19%). Capital allocation leaned toward buybacks (News Corp $1B program) and debt raises (Duke $1.3B notes), with M&A catalysts imminent (Alexander & Baldwin merger ~March 12). Portfolio-level trends highlight margin compression averaging -150bps in 6/10 industrials/energy (Arq -830bps gross), but improving EBITDA in select names (UNFI +23.4%, TWFG +47%). Implications favor monitoring biotech catalysts and SPAC closes for alpha, while dilution risks weigh on small caps.
Priority Breakdown: 50 filings analyzed — High: 23, Medium: 27, Low: 0
Key Events
8 events
Elevance Health/CMS Sanctions
Monitor resolution pre-March 31 effective date, FY26 guidance impact, prior 8-K March 2
◆
Arq/GAC Optimization
FY26 no GAC contribution, review outcome for EBITDA $17-20M guide, Q1 earnings for updates
◆
Lipocine/LPCN 1154
Phase 3 topline early April 2026, NDA mid-2026 potential, post-$24.7M cash raise
◆
+ 5 more events in full digest
Market Themes
6 themes
Biotech/Health Dilution Wave
8/12 biotech filings show equity raises (Aclaris $39.8M/12.7M sh, AN2 $40M, Lipocine ATM to $24.7M cash), avg +5-10% dilution but funds Phase 3 catalysts (LPCN 1154 Apr 2026), mixed sentiment implies near-term pressure but pipeline upside
●
SPAC/de-SPAC Momentum
6 filings with amendments/progress (IQM/RAAQ $1.8B/$175M trust, Horizon Quantum $111.9M PIPE reduction rights, Climate Transition $150M IPO), low redemptions key, Q2 2026 closes offer merger arb plays
●
Healthcare Guidance Resilience
4 majors reaffirm FY26 (Elevance $25.50 EPS despite sanctions Mar 31, Centene >$3.00, TransUnion confirms pre-Mexico acq), vs regs/CMS risks, sector avg benefit ratios stable
●
+ 3 more themes in full digest
Notable Developments
12 highlights
Pershing Square Capital Management(BULLISH)
S-1 for IPO highlights $2.1B Vantage Acquisition closing Q2 2026, core strategy of high-quality growth stakes, positive sentiment
▲
Elevance Health(BULLISH)
Reaffirmed FY26 adj EPS >=$25.50 and benefit ratio 90.2% +/-50bps despite CMS sanctions effective March 31, 2026, showing resilience
▲
Aclaris Therapeutics(BULLISH)
Sold 12.7M shares for $39.8M gross proceeds March 2-9 to institutional buyers like Deep Track Capital, bolstering cash without operational declines
▲
+ 9 more highlights in full digest
Compliance Alerts
10 alerts
Trio Petroleum(HIGH RISK)
$17.4M/18.1M shares sold via ATM since Jan 2026, only $1.6M left of $19M max, rapid fundraising implies heavy dilution
▼
Bullish(HIGH RISK)
FY25 net loss $785M vs +$80M in 2024 (digital assets fair value -$675M), sales -2% YoY to $244.8B, admin +19%
▼
U Power(HIGH RISK)
F-1 units at $1.31 with reset warrants to 50% exercise price, up to 21.1M extra shares, Nasdaq delist risk from $5M min value rule
▼
+ 7 more alerts in full digest
📂 View Complete Digest
View all 50 filings with complete AI analysis.
View Full Digest →

Live Market Intelligence. Delivered instantly.

We monitor global markets in real-time, synthesizing millions of unstructured data points into actionable signals before they hit the mainstream news cycle.

Live Intelligence Feed
Volatility: High
--:--
Connecting to Live Feed...Establishing secure connection to market intelligence streams
--:--
Awaiting SignalsMonitoring exchanges for new material disclosures
--:--
System ActiveEngine is processing unstructured data points
--:--
StandbyReady to synthesize the next alert
--:--
Connecting to Live Feed...Establishing secure connection to market intelligence streams
--:--
Awaiting SignalsMonitoring exchanges for new material disclosures
--:--
System ActiveEngine is processing unstructured data points
--:--
StandbyReady to synthesize the next alert
What lands in your inbox

This is a real alert. Not a notification — a briefing.

Every material SEC filing, distilled into a decision-ready brief — the company, the event, the AI analysis, the risks — in your inbox seconds after it hits the wire. Swipe through seven we actually sent.

GunpowderVisit Dashboard →

New SEC Filing Alert

June 08, 2026
Filing Details
VAIL RESORTS INC[MTN]
10-Q
June 08, 2026 at 12:00 AM ET
Accession: 0000812011-26-000026
HIGH PRIORITY
Event Intelligence
  • Event Types: Periodic Report, Financial Results
  • Category: Quarterly Results
AI Analysis

Sentiment: Mixed

Vail Resorts reported a decline in total net revenue for both the three and nine months ended April 30, 2026, compared to the same periods in 2025. Net income attributable to Vail Resorts decreased 19.3% to $314.4M for the quarter and 26.7% to $337.7M for the nine-month period. However, the company reduced total liabilities by $254.1M from July 2025 and improved stockholders' equity by $162.2M over the same period.

  • Lift revenue declined 5.3% to $729.4M for the quarter and 3.5% to $1.405B for the nine-month period.
  • Ski School revenue fell 11.5% to $141.8M for the quarter and 9.9% to $270.3M for the nine-month period.
  • Dining revenue decreased 10.7% to $99.1M for the quarter and 8.5% to $203.6M for the nine-month period.
  • Retail/Rental revenue declined 8.3% to $104.2M for the quarter and 6.2% to $261.0M for the nine-month period.
  • Owned hotel rooms revenue dropped 14.9% to $12.9M for the quarter and 4.5% to $54.0M for the nine-month period.
  • Managed condominium rooms revenue fell 13.1% to $28.3M for the quarter and 10.2% to $64.1M for the nine-month period.
  • Transportation revenue decreased 22.9% to $5.2M for the quarter and 17.2% to $11.4M for the nine-month period.
  • Interest expense increased 22.5% to $51.3M for the quarter and 19.4% to $152.1M for the nine-month period.
  • Provision for income taxes decreased 18.8% to $105.6M for the quarter and 25.6% to $117.3M for the nine-month period.
  • Cash and cash equivalents decreased 20.5% from $467.0M (April 30, 2025) to $371.4M (April 30, 2026).
  • Long-term debt due within one year decreased from $591.5M (April 30, 2025) to $73.5M (April 30, 2026), while long-term debt (net) increased from $2.119B to $2.950B over the same period.
  • Dividends declared per share remained flat at $2.22 per quarter and $6.66 for the nine-month period.
  • Weighted-average basic shares outstanding decreased 4.3% from 37,241 to 35,633 for the quarter.
SEC Summary: Filed: 2026-06-08 AccNo: 0000812011-26-000026 Size: 9 MB
View Full Filing

We monitor the exchanges and extract the key signals so you don't have to.

40+ daily digest streams extracted from exchanges and regulatory agencies—automatically summarized, organized, and delivered to your Email inbox, Slack, Telegram or Discord.

We monitor the exchanges and extract the key signals so you don't have to.

Advanced Daily Market Insights

Get concise AI-generated summaries highlighting market impact, sentiment, and key takeaways. Smart analysis sent daily at 9 PM. All AI analysed filings are accessible on the web app 24x7.

Advanced Daily Market Insights

Comprehensive filings monitoring. Covered.

Track investment signals, risks, red flags, insider activity, and notable developments from all exchanges and regulatory agencies from a single platform.

Comprehensive filings monitoring. Covered.

Smart Market Theme Analysis

Expert level market theme analysis for investors and traders. Get ahead of the market with our AI-powered key events highlights.

Smart Market Theme Analysis

SMART MONEY

Track what the best-informed money is doing.

Congressional disclosures, superinvestor 13F moves, and corporate insider activity — each scored, themed, and fused into one view. We surface the rare moments when all three lean the same way on the same stock.

The convergence signal

When a member of Congress buys, several superinvestor funds add, and corporate insiders buy the same stock inside 45 days — that is a convergence.

Illustrative — a hypothetical pattern, not a recommendation.

8 hours of reading.
8 minutes with Gunpowder.

SEC filings are long, dense, and time-consuming to read. Gunpowder's AI extracts key information in minutes, so your team can focus on analysis instead of document hunting.

Manual review: 8+ hours
Gunpowder: 5 minutes

From the Blog

// DAILY
{ United States }

VA Healthcare & Services Contracts — October 31, 2026

This digest covers a single Department of Veterans Affairs award: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP (Northfield, IL) for September 2026 medical-surgical prime vendor expenditures, awarded under full and open competition with no set-aside. The stream is 100% civilian (0/1 defense-related), so there is no DOD, NDAA, or continuing-resolution exposure to weigh; the relevant budget context is VA medical-supply appropriation continuity. The highest-conviction read is that this is a recurring monthly prime vendor spend report rather than a new multi-year program — total obligation equals base-plus-options at $88,992,131, the performance period is a single month (2026-09-01 to 2026-09-30), and outlays to date are $0. Signal strength is 4/10 and materiality 4/10, neutral: meaningful absolute dollars but no incremental option value and no confirmed annualization. Key risk/watch item: the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency and the absence of prior-month comparators mean the implied ~$1.07B annualized run-rate is unverified and should not be capitalized without recurrence data.

daily · October 31, 2026 · United States
// DAILY
[ United States ]

New Federal Contractors — October 31, 2026

The single award in this stream is an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) for September 2026 medical-surgical prime vendor expenditures, making the period 100% civilian (0/1 defense-related) and dominated by VA medical-supply procurement. The signal is neutral (4/10 strength, 4/10 materiality): the dollar value is meaningful, but the performance period is a single month (2026-09-01 to 2026-09-30), total obligation equals base-plus-options at $88,992,131 with zero option value, and $0 has been outlayed to date, indicating a recurring monthly spend report rather than a new multi-year program. The award was full and open competition with no set-aside, and Medline is explicitly designated 'Not a Small Business,' reinforcing an entrenched large-supplier relationship with the VA. Highest-conviction takeaway is the scale of VA medical-surgical distribution spend (~$89M in one month, implying a ~$1.07B annualized run-rate only if the pattern repeats, which the data does not confirm). Key watch item is whether comparable monthly Medline VA prime vendor awards recur, plus resolution of the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency and progression of outlays from $0.

daily · October 31, 2026 · United States
// DAILY
{ United States }

Significant Contract Modifications ($10M+) — October 31, 2026

This digest covers a single significant contract modification: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) for medical-surgical prime vendor expenditures. The award is 100% civilian (0 defense-related contracts), making the VA medical-supply channel the sole theme this period. The highest-conviction signal is neutral: the obligation is meaningful in absolute dollars but represents only a one-month performance period (2026-09-01 to 2026-09-30) with $0 outlayed to date and base-plus-options identical to the base value, indicating a recurring monthly prime vendor spend report rather than a new multi-year program. Full and open competition with no set-aside and a non-small-business recipient signals an entrenched large-supplier relationship, but no incremental option value is created. Key watch items are whether similar monthly Medline VA awards recur (which would validate a ~$1.07B annualized run-rate that the data does NOT confirm) and the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency.

daily · October 31, 2026 · United States
// DAILY
[ United States ]

Contract Deobligations Alert — October 31, 2026

This digest covers a single contract: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) for medical-surgical prime vendor expenditures for September 2026. The award is 100% civilian (VA), with zero defense-related obligations, and represents a recurring monthly spend report rather than a new multi-year program, as evidenced by a one-month performance period (2026-09-01 to 2026-09-30) and $0 outlayed to date. The highest-conviction signal is neutral: the dollar value is meaningful but short duration and no option value limit incremental revenue visibility. Key watch items include whether similar monthly VA prime vendor awards recur for Medline (to validate an annualized run-rate of ~$1.07B, which is not confirmed) and resolution of the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency. Overall, this is a low-risk, low-signal data point that underscores Medline's established VA supply relationship but offers limited actionable investment intelligence on its own.

daily · October 31, 2026 · United States
// DAILY
{ United States }

Contract Option Exercises — October 31, 2026

The sole contract in this digest is an $88.99M firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (VA) for medical-surgical prime vendor expenditures for September 2026. This is a civilian agency award, with 0 defense-related contracts, and represents a recurring monthly spend report rather than a new multi-year program, as the performance period is only one month and total obligation equals base-plus-options. The signal is neutral (strength 4/10, materiality 4/10) due to the short duration and lack of incremental option value, despite the meaningful dollar amount. The highest-conviction takeaway is that Medline remains an established large supplier to the VA under full and open competition with no set-aside, but the single data point does not confirm an annualized run-rate. Key risk is the inconsistency between the award date (2026-10-28) and the start date (2026-09-01), and the $0 outlay to date, which warrants monitoring for recurrence and actual spending progression.

daily · October 31, 2026 · United States
// DAILY
[ United States ]

High-Value Federal Grants ($5M+) — October 31, 2026

This period contains a single high-value federal award: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) for medical-surgical prime vendor expenditures for September 2026. The award is 100% civilian (0/1 defense-related), with no DOD exposure, so it carries no direct defense-sector or NDAA-alignment signal. The dominant theme is VA medical-surgical supply distribution, and the highest-conviction takeaway is that Medline holds an established, full-and-open, non-set-aside prime vendor relationship with the VA — a modest positive for its government channel but not a new program win. The critical caveat is duration: the performance period is a single month (2026-09-01 to 2026-09-30), total obligation equals base-plus-options at $88,992,131 with no option value, and $0 has been outlayed to date, indicating a recurring monthly spend report rather than a multi-year commitment. Key watch items are whether similar monthly VA prime vendor awards recur (which would validate an annualized run-rate of roughly $1.07B) and the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency.

daily · October 31, 2026 · United States
// DAILY
{ United States }

General Federal Contracts — October 31, 2026

This period contains a single federal contract action: an $88,992,131 firm-fixed-price delivery order to Medline Industries, LP from the Department of Veterans Affairs (SAC Frederick) covering September 2026 medical-surgical prime vendor expenditures. The split is 100% civilian ($88.99M) and 0% defense, with no DOD exposure and therefore no direct NDAA or defense-budget linkage. The dominant theme is recurring VA medical-surgical supply distribution through a full-and-open, no-set-aside prime vendor arrangement with an established large supplier. The highest-conviction read is neutral: the dollar value is material, but the performance period is a single month (2026-09-01 to 2026-09-30), base and base-plus-options are identical at $88,992,131 (zero option value), and $0 has been outlayed to date, indicating a monthly spend report rather than a new multi-year program. Key watch items are whether similar monthly VA prime vendor awards recur (which would validate a ~$1.07B annualized run-rate that the data does NOT confirm) and the award-date (2026-10-28) versus start-date (2026-09-01) inconsistency.

daily · October 31, 2026 · United States
// DAILY
[ United States ]

Biotech Small-Cap Approvals — October 30, 2026

This period's digest covers 4 FDA approvals, all classified as 'Other' (FALLBACK) with no NMEs, biosimilars, or label expansions, and all carrying neutral signals. The approvals are for rivaroxaban (Teva), tranexamic acid (Zydus), propranolol HCl (Senores), and epinephrine (Gland), each with limited disclosed commercial data. No dominant therapeutic area theme emerges, as the drugs span anticoagulation, antifibrinolysis, cardiovascular, and emergency care. The highest-conviction signal is neutral across the board, with no differentiated upside or downside identified. Key risk is the lack of disclosed peak sales, exclusivity, or pricing power, which limits investment actionability.

daily · October 30, 2026 · United States
// DAILY
{ United States }

New Drug Approvals (Original) — October 30, 2026

The October 30, 2026 FDA digest contains 4 approvals, all classified as 'Other' (FALLBACK) with 0 NMEs, 0 biosimilars, and 0 label expansions, yielding 4 neutral signals and no bullish or bearish catalysts. The four entries — rivaroxaban (Teva Pharms USA), tranexamic acid (Zydus Lifesciences), propranolol hydrochloride (Senores Pharms), and epinephrine (Gland) — are generic/duplicate-type filings rather than true biosimilars, despite the stream's biosimilar labeling, so originator erosion implications are limited and commercial data (peak sales, exclusivity, pricing power, market position) is NOT_DISCLOSED across all four. No therapeutic-area clustering of strategic significance emerges: the assets span anticoagulation, antifibrinolytic/hemostasis, cardiovascular beta-blockade, and emergency anaphylaxis, with no single TA gaining multiple high-value approvals. Highest-conviction signal is absent this period — no NME, no Breakthrough, Priority Review, Orphan, or Accelerated Approval designations were reported, so there is no differentiated commercial catalyst. Key watch item is whether these fallback generic entries signal early price erosion in the rivaroxaban (Xarelto) and epinephrine (EpiPen) classes, and whether any sponsor converts this cadence into higher-value pipeline events.

daily · October 30, 2026 · United States
// DAILY
[ United States ]

Federal Construction & Infrastructure Contracts — October 30, 2026

This digest covers a single federal construction award: a $69,535,671 firm-fixed-price definitive contract to Perini Management Services, Inc. (a Tutor Perini Corp subsidiary), awarded by the National Park Service under the Department of the Interior for rehabilitation of the Furnace Creek and Cow Creek water and wastewater treatment systems in Death Valley, CA. The award is 100% civilian (0/1 defense-related), so it carries no direct DOD or NDAA-driven signal and instead reflects Interior/NPS facility-infrastructure spending. The contract was full and open competition with no set-aside and the recipient is not a small business, indicating a merit-based win by an established contractor; the entire $69.5M is committed with no additional option ceiling disclosed. The highest-conviction signal is the backlog addition for Tutor Perini (~$21-23M/year across the ~32.4-month performance period from July 2026 to March 2029), though with $0 outlayed to date and a future award/start date this is forward-looking backlog rather than immediate revenue. Key watch items are confirmation of award finalization and cost performance under the firm-fixed-price structure, which shifts overrun risk to Perini.

daily · October 30, 2026 · United States
// DAILY
{ United States }

Defense Manufacturing Contracts — October 30, 2026

This digest covers a single Department of Homeland Security contract modification awarded to Sierra Nevada Company, LLC, valued at $70,401,585, with a date listed as 2023-09-28. The award is entirely civilian (0 of 1 defense-related), so it does not signal DOD procurement trends. The signal is neutral (5/10 strength, 5/10 materiality) due to unknown pricing structure, competition status, and revenue contribution. The highest-conviction takeaway is limited: Sierra Nevada remains a DHS counterparty, but the lack of detail on scope, competition, and contract type prevents a directional investment call. Key watch items include potential re-compete or option exercise dates and any follow-on DHS awards that could clarify Sierra Nevada's civilian franchise.

daily · October 30, 2026 · United States
// DAILY
[ United States ]

DHS Homeland Security Contracts — October 30, 2026

This digest covers a single Department of Homeland Security contract modification to Sierra Nevada Company, LLC valued at $70,401,585, dated 2023-09-28, with 0 of 1 contracts classified as defense-related, making this a purely civilian-agency signal. The award is a modification rather than a new competitive win, and the source analysis flags pricing structure, competition basis, and revenue contribution as unknown, yielding a neutral signal strength of 5/10 and materiality of 5/10. The dominant theme is DHS sustainment/modification spending concentrated in a single recipient, which offers limited breadth for sector-level inference. Highest-conviction read: Sierra Nevada remains an incumbent of record at DHS, but the absence of disclosed competition, pricing, and program detail caps conviction. Key watch item: the underlying program office, option/re-compete timeline, and whether this modification is funded under a continuing resolution, since October-adjacent DHS obligations carry CR and budget-cycle exposure.

daily · October 30, 2026 · United States

FAQ

Frequently asked questions

Gunpowder monitors all major SEC filing types including 10-K (annual reports), 10-Q (quarterly reports), 8-K (current reports), DEF 14A (proxy statements), 13-F (institutional holdings), and many more. Configure your alerts to focus on the filing types relevant to your research or compliance needs.

New filings are processed within minutes of being published to agency databases. AI summaries typically complete within 2-5 minutes, depending on document length. You will receive alerts shortly after processing is complete.

Yes! Beyond SEC filings, Gunpowder also monitors filings from the FDA, FCC, EPA, and other regulatory agencies. This gives you a comprehensive view of regulatory activity in one place.

Our AI reads through entire filings and extracts key information, including risk factors, notable disclosures, and important changes. The summaries are designed to give you the key takeaways in under 60 seconds.

Gunpowder integrates with Slack, Discord, email, and webhooks for alerts. We also offer API access for custom integrations with your existing workflow, CRM, or internal tools.

Yes, we offer a 14-day free trial with full access to all features. No credit card required. You can set up alerts for multiple companies and agencies during your trial period.